Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin Inhibitor

Dermatology

Volumn 224, Issue 3, 2012, Pages 204-208

  Peuvrel, L ^a   Qureux, G ^a   Brocard, A ^a   Saint Jean, M ^a   Drno, B ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Kinase inhibitors; Nails; Onychodystrophy; Paronychia; Skin toxicity; Temsirolimus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BICARBONATE; CHLORHEXIDINE; EVEROLIMUS; MOUTHWASH; POVIDONE IODINE; STEROID; TEMSIROLIMUS;

ADULT; AGED; CASE REPORT; CONSTIPATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; METASTASIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; PARONYCHIA; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; XEROSIS; YELLOW NAIL DISCOLORATION;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; NAIL DISEASES; SIROLIMUS; STEROIDS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84863784970     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000338893     Document Type: Review

References (27)

1. Populo H, Lopes JM, Soares P: The mtor signaling pathway in human cancer. Int J Mol Sci 2012; 13: 1886-1918.
2. Fasolo A, Sessa C: Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011; 20: 381-394.
3. Sibaud V, Dalenc F, Mourey L, Chevreau C: Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol 2011; 91: 584-585.
4. Robert C, Sibaud V: Manifestations cutanées des thérapies ciblées anticancéreuses, ed 1e. Toulouse, Privat, 2010.
5. Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME: The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and metaanalysis. Eur J Cancer 2012; 48: 340-346.
6. Mendiratta V, Jain A: Nail dyschromias. Indian J Dermatol Venereol Leprol 2011; 77: 652-658.
7. Baran R: Lichen planus of the nails mimicking the yellow nail syndrome. Br J Dermatol 2000; 143: 1117-1118.
8. Begaud B, Evreux JC, Jouglard J, Lagier G: Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie 1985; 40: 111-118.
9. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
10. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
12. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
13. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (radiant-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012.
14. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
15. De Masson A, Fouchard N, Mery-Bossard L, Dauendorffer JN: Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mtor inhibitors. Dermatology 2011; 223: 4-8.
16. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C: Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011; 59: 526-540.
17. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
18. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-1595.
19. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
20. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME: Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005; 77: 76-89.
21. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J: Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-1610.
22. Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, Mamzer-Bruneel MF, de Prost Y, Kreis H, Bodemer C: Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476-482.
23. Raju DL, Bitzan M: Sirolimus-associated chronic pyogenic periungual infection. Kidney Int 2007; 71: 476.
24. Mahe E, Morelon E, Lechaton S, Kreis H, De Prost Y, Bodemer C: Sirolimus-induced onychopathy in renal transplant recipients. Ann Dermatol Vénéréol 2006; 133: 531-535.
25. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E: mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010; 24: 149-156.
26. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H: Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845-851.
27. Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL: Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009; 56: 82-88.